Table of Content

1. Executive Summary
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Neuroprotection Market

4. Market Overview
    4.1. Market Segmentation
        4.1.1. Segment Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Neuroprotection Market Analysis and Forecast, 2017-2031

5. Key Insights
    5.1. Pipeline Analysis
    5.2. Disease Prevalence & Incidence Rate Globally with Key Countries
    5.3. COVID-19 Pandemic Impact on Industry

6. Neuroprotection Market Analysis and Forecast, By Product
    6.1. Introduction and Definitions
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, By Product, 2017–2031
        6.3.1. Free Radical Trapping Agents (Antioxidants)
        6.3.2. Glutamate Antagonists (Anti-excitotoxic Agents)
        6.3.3. Apoptosis Inhibitors
        6.3.4. Anti-inflammatory Agents
        6.3.5. Neurotrophic Factors (NTFs)
        6.3.6. Metal Ion Chelators
        6.3.7. Stimulants
        6.3.8. Others
    6.4. Market Attractiveness, By Product

7. Global Neuroprotection Market Analysis and Forecast, by Application
    7.1. Introduction and Definitions
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2017–2031
        7.3.1. Prevention
        7.3.2. Treatment
    7.4. Market Attractiveness, by Application

8. Global Neuroprotection Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2017–2031
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness, by Region

9. North America Neuroprotection Market Analysis and Forecast
    9.1. Introduction
        9.1.1. Key Findings
    9.2. Market Value Forecast, By Product, 2017–2031
        9.2.1. Free Radical Trapping Agents (Antioxidants)
        9.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
        9.2.3. Apoptosis Inhibitors
        9.2.4. Anti-inflammatory Agents
        9.2.5. Neurotrophic Factors (NTFs)
        9.2.6. Metal Ion Chelators
        9.2.7. Stimulants
        9.2.8. Others
    9.3. Market Value Forecast, by Application, 2017–2031
        9.3.1. Prevention
        9.3.2. Treatment
    9.4. Market Value Forecast, by Country, 2023–2031
        9.4.1. U.S.
        9.4.2. Canada
    9.5. Market Attractiveness Analysis
        9.5.1. By Product
        9.5.2. By Application
        9.5.3. By Country

10. Europe Neuroprotection Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, By Product, 2017–2031
        10.2.1. Free Radical Trapping Agents (Antioxidants)
        10.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
        10.2.3. Apoptosis Inhibitors
        10.2.4. Anti-inflammatory Agents
        10.2.5. Neurotrophic Factors (NTFs)
        10.2.6. Metal Ion Chelators
        10.2.7. Stimulants
        10.2.8. Others
    10.3. Market Value Forecast, by Application, 2017–2031
        10.3.1. Prevention
        10.3.2. Treatment
    10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        10.4.1. Germany
        10.4.2. U.K.
        10.4.3. France
        10.4.4. Italy
        10.4.5. Spain
        10.4.6. Rest of Europe
    10.5. Market Attractiveness Analysis
        10.5.1. By Product
        10.5.2. By Application
        10.5.3. By Country/Sub-region

11. Asia Pacific Neuroprotection Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, By Product, 2017–2031
        11.2.1. Free Radical Trapping Agents (Antioxidants)
        11.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
        11.2.3. Apoptosis Inhibitors
        11.2.4. Anti-inflammatory Agents
        11.2.5. Neurotrophic Factors (NTFs)
        11.2.6. Metal Ion Chelators
        11.2.7. Stimulants
        11.2.8. Others
    11.3. Market Value Forecast, by Application, 2017–2031
        11.3.1. Prevention
        11.3.2. Treatment
    11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        11.4.1. China
        11.4.2. Japan
        11.4.3. India
        11.4.4. Australia & New Zealand
        11.4.5. Rest of Asia Pacific
    11.5. Market Attractiveness Analysis
        11.5.1. By Product
        11.5.2. By Application
        11.5.3. By Country/Sub-region

12. Latin America Neuroprotection Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, By Product, 2017–2031
        12.2.1. Free Radical Trapping Agents (Antioxidants)
        12.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
        12.2.3. Apoptosis Inhibitors
        12.2.4. Anti-inflammatory Agents
        12.2.5. Neurotrophic Factors (NTFs)
        12.2.6. Metal Ion Chelators
        12.2.7. Stimulants
        12.2.8. Others
    12.3. Market Value Forecast, by Application, 2017–2031
        12.3.1. Prevention
        12.3.2. Treatment
    12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        12.4.1. Brazil
        12.4.2. Mexico
        12.4.3. Rest of Latin America
    12.5. Market Attractiveness Analysis
        12.5.1. By Product
        12.5.2. By Application
        12.5.3. By Country/Sub-region
13. Middle East & Africa Neuroprotection Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, By Product, 2017–2031
        13.2.1. Free Radical Trapping Agents (Antioxidants)
        13.2.2. Glutamate Antagonists (Anti-excitotoxic Agents)
        13.2.3. Apoptosis Inhibitors
        13.2.4. Anti-inflammatory Agents
        13.2.5. Neurotrophic Factors (NTFs)
        13.2.6. Metal Ion Chelators
        13.2.7. Stimulants
        13.2.8. Others
    13.3. Market Value Forecast, by Application, 2017–2031
        13.3.1. Prevention
        13.3.2. Treatment
    13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
        13.4.1. GCC Countries
        13.4.2. South Africa
        13.4.3. Rest of Middle East & Africa
    13.5. Market Attractiveness Analysis
        13.5.1. By Product
        13.5.2. By Application
        13.5.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2022)
    14.3. Company Profiles
        14.3.1. Daiichi Sankyo Company
            14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.1.2. Treatment Type Portfolio
            14.3.1.3. Financial Overview
            14.3.1.4. SWOT Analysis
            14.3.1.5. Strategic Overview
        14.3.2. Eli Lilly and Company
            14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.2.2. Treatment Type Portfolio
            14.3.2.3. Financial Overview
            14.3.2.4. SWOT Analysis
            14.3.2.5. Strategic Overview
        14.3.3. AbbVie Inc.
            14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.3.2. Treatment Type Portfolio
            14.3.3.3. Financial Overview
            14.3.3.4. SWOT Analysis
            14.3.3.5. Strategic Overview
        14.3.4. Dr. Reddy’s Laboratories Ltd.
            14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.4.2. Treatment Type Portfolio
            14.3.4.3. Financial Overview
            14.3.4.4. SWOT Analysis
            14.3.4.5. Strategic Overview
        14.3.5. Teva Pharmaceutical Industries Ltd.
            14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.5.2. Treatment Type Portfolio
            14.3.5.3. Financial Overview
            14.3.5.4. SWOT Analysis
            14.3.5.5. Strategic Overview
        14.3.6. Novartis AG
            14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.6.2. Treatment Type Portfolio
            14.3.6.3. Financial Overview
            14.3.6.4. SWOT Analysis
            14.3.6.5. Strategic Overview
        14.3.7. AstraZeneca plc.
            14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.7.2. Treatment Type Portfolio
            14.3.7.3. Financial Overview
            14.3.7.4. SWOT Analysis
            14.3.7.5. Strategic Overview
        14.3.8. Astrocyte Pharmaceuticals, Inc.
            14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.8.2. Treatment Type Portfolio
            14.3.8.3. Financial Overview
            14.3.8.4. SWOT Analysis
            14.3.8.5. Strategic Overview
        14.3.9. F. Hoffmann-La Roche AG
            14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.9.2. Treatment Type Portfolio
            14.3.9.3. Financial Overview
            14.3.9.4. SWOT Analysis
            14.3.9.5. Strategic Overview
        14.3.10. Biogen Inc.
            14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            14.3.10.2. Treatment Type Portfolio
            14.3.10.3. Financial Overview
            14.3.10.4. SWOT Analysis
            14.3.10.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Neuroprotection Market Value Share Analysis, By Product 2022 and 2031

Figure 03: Global Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

Figure 04: Global Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

Figure 05: Global Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

Figure 06: Global Neuroprotection Market Value Share Analysis, by Region, 2022 and 2031

Figure 07: Global Neuroprotection Market Attractiveness Analysis, by Region, 2023–2031

Figure 08: North America Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

Figure 09: North America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

Figure 10: North America Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

Figure 11: North America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

Figure 12: North America Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

Figure 13: North America Neuroprotection Market Value Share Analysis, by Country, 2022 and 2031

Figure 14: North America Neuroprotection Market Attractiveness Analysis, by Country, 2023–2031

Figure 15: Europe Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

Figure 16: Europe Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

Figure 17: Europe Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

Figure 18: Europe Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

Figure 19: Europe Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

Figure 20: Europe Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: Europe Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 22: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

Figure 23: Asia Pacific Neuroprotection Market Value Share Analysis, By Product 2022 and 2031

Figure 24: Asia Pacific Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

Figure 25: Asia Pacific Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

Figure 26: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

Figure 27: Asia Pacific Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 28: Asia Pacific Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 29: Latin America Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

Figure 30: Latin America Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

Figure 31: Latin America Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

Figure 32: Latin America Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

Figure 33: Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

Figure 34: Latin America Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 35: Latin America Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 36: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, 2017–2031

Figure 37: Middle East & Africa Neuroprotection Market Value Share Analysis, By Product, 2022 and 2031

Figure 38: Middle East & Africa Neuroprotection Market Attractiveness Analysis, By Product, 2023–2031

Figure 39: Middle East & Africa Neuroprotection Market Value Share Analysis, by Application, 2022 and 2031

Figure 40: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Application, 2023–2031

Figure 41: Middle East & Africa Neuroprotection Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 42: Middle East & Africa Neuroprotection Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 43: Global Neuroprotection Market Share Analysis, by Company, 2022

List of Tables

List of Tables

Table 01: Global Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

Table 02: Global Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Neuroprotection Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

Table 05: North America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 06: North America Neuroprotection Market Value (US$ Mn) Forecast, by Country, 2023–2031

Table 07: Europe Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

Table 08: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 09: Europe Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

Table 11: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: Asia Pacific Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Latin America Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

Table 14: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 15: Latin America Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 16: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, By Product, 2017–2031

Table 17: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Middle East & Africa Neuroprotection Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031